A novel mechanism of post-translational modulation of HMGA functions by the histone chaperone nucleophosmin

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Arnoldo, Laura ^a   Sgarra, Riccardo ^a   Chiefari, Eusebio ^b   Iiritano, Stefania ^b   Arcidiacono, Biagio ^b   Pegoraro, Silvia ^a   Pellarin, Ilenia ^a   Brunetti, Antonio ^b   Manfioletti, Guidalberto ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONE; DNA; HIGH MOBILITY GROUP A PROTEIN; IGFBP1 PROTEIN, HUMAN; INSULIN RECEPTOR; NUCLEAR PROTEIN; NUCLEOPHOSMIN; PROTEIN BINDING; SMALL INTERFERING RNA; SOMATOMEDIN BINDING PROTEIN 1;

AMINO ACID SEQUENCE; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMISTRY; GENETIC TRANSCRIPTION; GENETICS; HEPG2 CELL LINE; HUMAN; METABOLISM; MOLECULAR GENETICS; PROMOTER REGION; PROTEIN PROCESSING; PROTEIN TERTIARY STRUCTURE; REGULATORY SEQUENCE; RNA INTERFERENCE;

AMINO ACID SEQUENCE; BINDING SITES; DNA; HEP G2 CELLS; HISTONE CHAPERONES; HMGA PROTEINS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; MOLECULAR SEQUENCE DATA; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, INSULIN; REGULATORY SEQUENCES, NUCLEIC ACID; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC;

EID: 84923641991     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep08552     Document Type: Article

References (43)

1. Sgarra, R. et al. Nuclear phosphoproteins HMGA and their relationship with chromatin structure and cancer. FEBS Lett. 574, 1-8 (2004).
2. Foti, D., Iuliano, R., Chiefari, E. & Brunetti, A. A nucleoprotein complex containing Sp1, C/EBP beta, and HMGI-Y controls human insulin receptor gene transcription. Mol. Cell. Biol. 23, 2720-2732 (2003).
3. Foti, D. et al. Lack of the architectural factor HMGA1 causes insulin resistance and diabetes in humans and mice. Nat. Med. 11, 765-773 (2005).
4. Chiefari, E. et al. HMGA1 is a novel downstream nuclear target of the insulin receptor signaling pathway. Sci Rep. 2, 251; DOI:10.1038/srep00251 (2012).
5. Thanos, D. & Maniatis, T. Virus induction of human IFN beta gene expression requires the assembly of an enhanceosome. Cell 83, 1091-1100 (1995).
6. Yie, J., Merika, M., Munshi, N., Chen, G. & Thanos, D. The role of HMG I(Y) in the assembly and function of the IFN-beta enhanceosome. EMBO J. 18, 3074-3089 (1999).
7. Reeves, R., Edberg, D. D. & Li, Y. Architectural transcription factor HMGI(Y) promotes tumor progression and mesenchymal transition of human epithelial cells. Mol. Cell. Biol. 21, 575-594 (2001).
8. Shah, S. N. et al. HMGA1: a master regulator of tumor progression in triple-negative breast cancer cells. Plos One 8, e63419 (2012).
9. Pegoraro, S. et al. HMGA1 promotes metastatic processes in basal-like breast cancer regulating EMT and stemness. Oncotarget 4, 1293-1308 (2013).
10. Thuault, S. et al. Transforming growth factor-beta employs HMGA2 to elicit epithelial-mesenchymal transition. J. Cell Biol. 174, 175-183 (2006).
11. Cleynen, I. et al. Transcriptional control of the human high mobility group A1 gene: basal and oncogenic Ras-regulated expression. Cancer Res. 67, 4620-4629 (2007).
12. Akaboshi, S. et al. HMGA1 is induced by Wnt/beta-catenin pathway and maintains cell proliferation in gastric cancer. Am. J. Pathol. 175, 1675-1685 (2009).
13. Lee, Y. S. & Dutta, A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev. 21, 1025-1030 (2007).
14. Lee, S. et al. Histone deacetylase regulates high mobility group A2-targeting microRNAs in human cord blood-derived multipotent stem cell aging. Cell. Mol. Life Sci. 68, 325-336 (2011).
15. Lin, Y. et al. miR-26a inhibits proliferation and motility in bladder cancer by targeting HMGA1. FEBS Lett. 587, 2467-2473 (2013).
16. Zhou, H. et al. MicroRNA-26a acts as a tumor suppressor inhibiting gallbladder cancer cell proliferation by directly targeting HMGA2. Int. J. Oncol. 44, 2050-2058 (2014).
17. Chiefari, E. et al. Pseudogene-mediated posttranscriptional silencing of HMGA1 can result in insulin resistance and type 2 diabetes. Nat. Commun, 1, 40, DOI:10.1038/ncomms1040 (2010).
18. Zhang, Q. & Wang, Y. HMG modifications and nuclear function. Biochim. Biophys. Acta 1799, 28-36 (2010).
19. Sgarra, R. et al. Discovering high mobility group A molecular partners in tumour cells. Proteomics 5, 1494-1506 (2005).
20. Sgarra, R. et al. Interaction proteomics of the HMGA chromatin architectural factors. Proteomics 8, 4721-4732 (2008).
21. Malini, E. et al. HMGA Interactome: new insights from phage display technology. Biochemistry 50, 3462-3468 (2011).
22. Sgarra, R. et al. Macroscopic differences in HMGA oncoproteins post-translational modifications: C-terminal phosphorylation of HMGA2 affects its DNA binding properties. J. Proteome Res. 8, 2978-2989 (2009).
23. Brunetti, A.,Manfioletti, G., Chiefari, E. & Goldfine, I. D., Foti, D. 'Transcriptional regulation of human insulin receptor gene by the high-mobility group protein HMGI(Y). FASEB, 15, 492-500 (2001).
24. Okuwaki, M., Tsujimoto, M. & Nagata, K. The RNA binding activity of a ribosome biogenesis factor, nucleophosmin/B23, is modulated by phosphorylation with a cell cycle-dependent kinase and by association with its subtype. Mol. Biol. Cell 13, 2016-2030 (2002).
25. Grisendi, S., Mecucci, C., Falini, B. & Pandolfi, P. P. Nucleophosmin and cancer. Nat. Rev. Cancer 6, 493-505 (2006).
26. Okuwaki, M. The structure and functions of NPM1/Nucleophosmin/B23, a multifunctional nucleolar acidic protein. J. Biochem. 143, 441-448 (2008).
27. Okuwaki, M., Matsumoto, K., Tsujimoto, M. & Nagata, K. Function of nucleophosmin/B23, a nucleolar acidic protein, as a histone chaperone. FEBS Lett. 506, 272-276 (2001).
28. Hingorani, K., Szebeni, A. & Olson, M. O. Mapping the functional domains of nucleolar protein B23. J Biol Chem. 275, 24451-24457 (2000).
29. Lai, J. S. & Herr, W. Ethidium bromide provides a simple tool for identifying genuine DNA-independent protein associations. Proc. Natl. Acad. Sci. USA 89, 6958-6962 (1992).
30. Ellis, R. J. Molecular chaperones: assisting assembly in addition to folding. Trends Biochem. Sci. 31, 395-401 (2006).
31. Park, Y. J. & Luger, K. Histone chaperones in nucleosome eviction and histone exchange. Curr. Opin. Struct. Biol. 18, 282-289 (2008).
32. Samad, M. A., Okuwaki, M., Haruki, H. & Nagata, K. Physical and functional interaction between a nucleolar protein nucleophosmin/B23 and adenovirus basic core proteins. FEBS Lett. 581, 3283-3288 (2007).
33. Arlotta, P. et al. High mobility group I proteins interfere with the homeodomains binding to DNA. J. Biol. Chem. 272, 29904-29910 (1997).
34. Gadad, S. S. et al. The multifunctional protein nucleophosmin (NPM1) is a human linker histone H1 chaperone. Biochemistry 50, 2780-2789 (2011).
35. Swaminathan, V., Kishore, A. H., Febitha, K. K. & Kundu, T. K. Human histone chaperone nucleophosmin enhances acetylation-dependent chromatin transcription. Mol. Cell. Biol. 25, 7534-7545 (2005).
36. Kondo, T. et al. Identification and characterization of nucleophosmin/B23/numatrin which binds the anti-oncogenic transcription factor IRF-1 and manifests oncogenic activity. Oncogene 15, 1275-1281 (1997).
37. Inouye, C. J. & Seto, E. Relief of YY1-induced transcriptional repression by protein-protein interaction with the nucleolar phosphoprotein B23. J. Biol. Chem. 269, 6506-6510 (1994).
38. Lee, C. K., Shibata, Y., Rao, B., Strahl, B. D. & Lieb, J. D. Evidence for nucleosome depletion at active regulatory regions genome-wide. Nat. Genet. 36, 900-905 (2004).
39. Chiefari, E. et al. Functional variants of the HMGA1 gene and type 2 diabetes mellitus. JAMA 305, 903-912 (2011).
40. Liu, L. et al. Polymorphism of HMGA1 is associated with increased risk of type 2 diabetes among Chinese individuals. Diabetologia 55, 1685-1688 (2012).
41. Chiefari, E. et al. A polymorphism of HMGA1 is associated with increased risk of metabolic syndrome and related components. Sci. Rep. 3, 1491; DOI: 10.1038/srep01491 (2013).
42. Arcidiacono, B. et al. Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms. Exp. Diabetes Res. 2012, 789174 (2012).
43. Wolpin, B. M. et al. Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J. Clin. Oncol. 27, 176-85 (2009).